Pay in 4 interest-free payments of $8.75 Learn more
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10
JNK-IN-8 also exhibits exceptional selectivity based upon KinomeScan and enzymatic profiling
GSK0660 (100 nM) reduces CPT1a (a PPARβ/δ target gene) expression below the basal vehicle-treated level by approximately 50%
Functional characterization of CFI-402257
In recent studies
identified by a high-throughput screening
ESI-09 - CAS# 263707-16-0 size:2mg solid JNK-IN-8 also exhibits exceptional selectivityESI 09, CAS No. 263707 16 0, is a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC mediated Rap1 activation and Akt phosphorylation, as well as EPAC mediated insulin secretion in pancreatic cells. EPAC1 plays an important role in pancreatic cancer cell migration and invasion, and thus represents a potential target for developing novel therapeutic strategies for pancreatic cancer. Product